- 暂无内容
- . Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8 + T cell exhaustion and anti-PD-1 resistance. CELL REPORTS MEDICINE, 5, 2024.
- . Urolithin A Hijacks ERK1/2-ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity. Advanced Science, 2024.
- 武专昌. Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 8, 2024.
- . Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. SCIENCE TRANSLATIONAL MEDICINE, 15, 2024.
- 张言坤. ZHX2 emerges as a negative regulator of mitochondrial oxidative phosphorylation during acute liver injury. NATURE COMMUNICATIONS, 14, 2024.
- 一种TIM-3/CD28融合蛋白及所述融合蛋白修饰的CAR-T细胞
- 一种人可溶性TIM-4蛋白在制备抗肿瘤药物中的应用
- 一种靶向Siglec-9促进免疫细胞抗肿瘤和抗病毒功能小分子抑制剂及其应用
- 一种Toll样受体激动剂纳米粒子及其制备方法和应用
- 尿石素A及其衍生物在肿瘤免疫治疗的应用
- （包干项目）Tim-3通过Nur77调控单核细胞分化参与多发性硬化的作用及机制研究, 2024/01/01-2026/12/31
- 尿石素A结合ERK诱导线粒体自噬增强CAR-T细胞记忆表型和抗肿瘤效应的机制研究, 2022/09/07-2026/12/31
- 免疫细胞技术开发及升级, 2022/04/01-2025/04/30
- 介导HBV肝脏免疫耐受/耗竭的关键卡控点的发现与验证, 2021/12/01-2024/11/30
- 肿瘤免疫逃逸关键抑制分子的鉴定及多靶向纳米抗体制备, 2020/12/16-2023/12/31
- 暂无内容